---
title: "Pembrolizumab in Combination with Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer"
canonical: "https://www.renown.org/clinical-trials-directory/NCT06524544"
last_updated: "2026-10-09T22:11:27Z"
---

# Pembrolizumab in Combination with Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer

URL: https://www.renown.org/clinical-trials-directory/NCT06524544

Short Title: EA8231

Enrollment Status: Recruiting

NCT #: [NCT06524544](https://clinicaltrials.gov/study/NCT06524544)

Specialty Area: Oncology

Condition Studied: Urothelial Cancer

Age Groups: Adult; Older Adult

Sex: All

Study Type: Interventional

Accepts Healthy Volunteers: No

Principal Investigator: Shi-Ming Tu, MD

Complete Study Details: https://clinicaltrials.gov/study/NCT06524544

## Study Information

### Summary / Purpose

The purpose of this study is to compare the usual treatment of chemotherapy to using pembrolizumab plus Sacituzumab govitecan-hziy for patients with urothelial cancer. The combination of pembrolizumab and Sacituzumab govitecan-hziy could shrink your cancer or prevent it from growing.

### Who Can Participate

- Adults 18+ years of age
- Confirmed locally advanced or metastatic urothelial cancer
- Must have measurable disease
- Must have had at least 1 line of systemic therapy given

### What's Involved

- Random assignment to receive either pembrolizumab plus sacituzumab govitecan, both given intravenously (IV), or standard IV chemotherapy chosen by your doctor
- Standard IV chemotherapy, which may include cisplatin or carboplatin with gemcitabine, docetaxel, or paclitaxel, for participants assigned to that group
- Imaging with computed tomography (CT) scans or magnetic resonance imaging (MRI) scans
- Sample collection for research
- Completing questionnaires about your bladder cancer symptoms, fatigue, and quality of life

## Additional Information

Location: Renown Health, Office of Clinical Research

Address: 1500 E 2nd St. Reno, NV 89502

General Research: [775-982-3646](tel:775-982-3646)

Oncology Research: [775-982-5050](tel:775-982-5050)

Email: [Renown-CRD@renown.org](mailto:Renown-CRD@renown.org)
